Axogen reports inducement grants under Nasdaq listing rule

Axogen, Inc. announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will be responsible for Financial Planning and Analysis and Investor Relations.

Tamayo has over 20 years of experience in healthcare and life sciences including as a division CFO and in leadership roles in Investor Relations and Corporate FP&A in companies such as McKesson, Merck, Novartis, and CVS Health. Most recently he served as Interim CFO of Neighborhood LTC Pharmacy, a technology healthcare management and pharmacy company in Lincoln, NE. Prior to this he served as SVP Corporate Finance, M&A, Investor Relations for McKesson, a diversified healthcare company. Tamayo earned his Bachelor of Science in Electrical Engineering from Florida International University, followed by dual master’s degrees in business administration and industrial engineering from the University of Miami.

In connection with the commencement of his employment on November 27, 2023, and as a material inducement of employment, Tamayo was awarded an equity grant on December 1, 2023, consisting of (i) non-qualified stock options to purchase 65,800 shares of the Company’s common stock and (ii) non-qualified restricted stock units (“RSUs”) representing 37,500 shares of the Company’s common stock. The stock options have an exercise price of $6.88 per share, a 10-year term, and will vest over a four-year period, with 50% vesting after the second year and 12.5% of the total shares granted vesting every six months thereafter for the next two years. The RSUs are subject to vesting over 4 years, with 50% vesting after the second year and 25% of the total shares granted vesting every year thereafter for the next two years.
MB Bureau